Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Giuseppe Santini
Single-Inhaler Triple Therapy Utilizing the Once-Daily Combination of Fluticasone Furoate, Umeclidinium and Vilanterol in the Management of COPD: The Current Evidence Base and Future Prospects
Therapeutic Advances in Respiratory Disease
Pulmonary
Respiratory Medicine
Pharmacology
Related publications
Evidence-Based Review of Data on the Combination Inhaler Umeclidinium/Vilanterol in Patients With COPD
International Journal of COPD
Environmental
Public Health
Health Policy
Medicine
Pulmonary
Respiratory Medicine
Occupational Health
Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients
American Journal of Respiratory and Critical Care Medicine
Pulmonary
Critical Care
Respiratory Medicine
Intensive Care Medicine
A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/Salmeterol in Moderate to Very Severe COPD
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Patient Considerations in the Treatment of COPD: Focus on the New Combination Inhaler Umeclidinium/Vilanterol
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
Once-Daily Fluticasone Furoate/Vilanterol Combination Versus Twice-Daily Budesonide/Formoterol Combination in the Treatment of Controlled Stable Asthma: A Randomized Crossover Trial
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Integrated Safety and Efficacy Analysis of Once-Daily Fluticasone Furoate for the Treatment of Asthma
Respiratory Research
Pulmonary
Respiratory Medicine
Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma
Respiratory Research
Pulmonary
Respiratory Medicine
Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial
Thorax
Pulmonary
Respiratory Medicine
